Hana Field: Okay, I have to ask before we start — did you see anything about the German healthcare figures this week? Because I sent you that link and then couldn't stop thinking about it.
Iris Holm: The 12.8% of GDP figure. Yes. It's the number that breaks the standard argument.
Hana Field: Right — because Germany is spending the highest share of GDP on healthcare in the entire EU, and yet the whole shape of the problem doesn't change. 89% covered through compulsory insurance, this whole multi-payer architecture with private and nonprofit insurers and public oversight, the most serious attempt anyone has made at synthesizing equity and market mechanisms, and the wall is still there.
Iris Holm: The wall was always structural. Not financial.
Hana Field: And that's what I want to dig into today — this question of whether any health system, anywhere, actually solves both problems, or whether every country is just deciding which heartbreak it can live with.
Iris Holm: OECD research makes that concrete. No model consistently dominates on all performance indicators. Not the NHS. Not the US system. Not Germany. Every system surrenders something.
Hana Field: Wait — so not even on specific indicators? Like, you'd expect some model to just win on access, say.
Iris Holm: Consistently across all indicators? None. That's the load-bearing fact. It means the equity-efficiency tradeoff isn't a policy failure — it's architecture. Mechanisms that distribute resources fairly tend to reduce the profit incentives that drive innovation. You can't dissolve that tension by spending more.
Hana Field: And Germany is the proof. If Germany can't outspend the tradeoff, nobody can.
Iris Holm: So: every nation is choosing which form of inequality to live with, not which to eliminate. That's the thesis.
Hana Field: And the way I keep explaining it to myself — and tell me if this lands — it's a neighborhood pool versus a private gym. Pool lets everyone swim, but the lanes fill up. Gym has better equipment, but you have to be a member. Neither one solves both problems. You just pick which problem you'd rather have.
Iris Holm: That's it. And the uncomfortable part is that the choice is deliberate — not accidental.
Hana Field: But deliberate is actually the part that unsettles me — because the NHS in 1948 didn't say 'we choose rationing.' They said everyone deserves care, full stop, and the rationing came later as the budget constraint made itself felt.
Iris Holm: The 1948 founding embedded equity as the principle. Budget constraint was always the mechanism. Those aren't separate decisions.
Hana Field: Right — but the part that doesn't fit is that the people who built the NHS didn't think they were signing up for a system where a drug proven effective in trials would just be... unavailable. That consequence came much later.
Iris Holm: NICE exists precisely because of that. A cost-benefit threshold that determines which drugs the NHS will fund. And right now there's an immunotherapy treatment, proven in trials, available in Frankfurt, available in Boston, blocked in London because the ratio doesn't clear the threshold. Not because it doesn't work.
Hana Field: Wait — it's approved elsewhere in Europe?
Iris Holm: Frankfurt specifically. Which means two patients, identical stage-four cancer, one in London and one in Germany — different drugs, under systems that both call themselves universal. That's my flag in the ground. 'Universal' is a marketing term, not a structural guarantee.
Hana Field: No, I don't buy that framing. And actually — I want to push on it, because what you're describing is visible rationing. The woman in the NHS clinic gets told no. She knows she was told no. She can fight it, escalate it, go to the press.
Iris Holm: She still doesn't get the drug.
Hana Field: But in a market system — Canada's Medicare has this too, the provincial rationing mechanisms are real — the patient who can't afford the specialist who would prescribe it doesn't even reach the conversation where someone says no. She doesn't know what she's missing. That's rationing too. It's just invisible, and I think invisible is actually worse.
Iris Holm: The question is whether 'visible' makes the outcome less bad. She still doesn't have the drug.
Hana Field: It makes the system accountable in a way that a coverage gap never is. Risk pooling — sharing the financial burden across a mandatory population — is what makes that visibility possible. The NHS, Canada's Medicare, the WHO's whole framework for universal health coverage, they all rest on that mechanism. The market system just doesn't build it in.
Iris Holm: So your flag is: public rationing is honest, market exclusion is hidden. Fair. But both flags are planted in the same cemetery.
Hana Field: And I think that's exactly where we are — because neither of us is wrong, and that's the problem.
Iris Holm: Except that cemetery was built somewhere. And the United States is where the construction money came from.
Hana Field: The R&D argument.
Iris Holm: The U.S. leads in pharmaceutical R&D investment and new drug launches. That immunotherapy drug in Frankfurt? Private capital chasing patent-protected profit built it. Remove that incentive and you don't just clean up the billing department — you lose the drug.
Hana Field: But who does that drug serve — actually serve — if the pricing puts it out of reach for everyone without platinum-tier insurance? And I mean, the coverage gaps in the U.S. aren't accidents. Baicker, Chandra, Shepard — they frame this explicitly. It's a choice between correcting market failures versus providing a social floor. Those are two different projects. The gaps aren't bugs in the American system, they're how market-based coverage is actually organized.
Iris Holm: I know the Baicker framing. It's right. But it doesn't answer the counterfactual.
Hana Field: No — wait, I think it does, though? Because the market failure isn't just coverage gaps. Adverse selection, moral hazard, information asymmetry, monopoly pricing — those aren't edge cases, they're the reason public intervention exists at all. And then the fix, the regulation that corrects those failures, erodes the profit incentive that drives the innovation. So the U.S. is caught — it can't regulate its way to equity without threatening the exact engine you're defending.
Iris Holm: Agreed. That tension is real. But the administrative overhead number makes your case stronger than the market failure argument does.
Hana Field: Oh — say more.
Iris Holm: Market-based systems generate significantly higher administrative overhead. Billing, insurer negotiation, claims processing, compliance. That's not waste you can optimize away — it's structurally produced by multi-payer architecture. The competition that's supposed to drive efficiency is actually generating transaction costs that partially cancel the efficiency claim.
Hana Field: So the innovation engine is running, and a meaningful share of what it produces is going to — paperwork.
Iris Holm: Frankly, yes. And private capital is extracting profit on top of that overhead. So the efficiency advantage of market systems — the theoretical one — gets eaten from both ends.
Hana Field: And you know, there's someone inside that overhead — someone who spends forty minutes on hold with an insurer trying to get a claim processed while they're recovering from surgery. That's not an abstraction. The administrative complexity is not a fixable inefficiency, it's actually how the system is organized, and real people are navigating it sick.
Iris Holm: Look — I don't dispute the cost. The question is whether the innovation output justifies it. And research suggests public reimbursement policy can actually dampen innovation incentives — meaning the moment you fix the overhead problem through a single-payer structure, you may be trading administrative waste for slower drug development.
Hana Field: And that's exactly where Germany and the Netherlands and Switzerland start looking interesting — because they're trying to manage that specific tradeoff, not solve it, and how close they get is the part we should probably pull on next.
Iris Holm: And that's exactly where the concession lives — I'll give you Germany, the Netherlands, Switzerland. Compulsory, universal, delivered through regulated private insurers. They do distribute the pain more smoothly than a pure market system or a pure public one. I'll grant that.
Hana Field: Wait — that's a real concession from you.
Iris Holm: It is. But 'more smoothly' is not 'structurally resolved.' Germany still rations. 12.8% of GDP and they still ration. The social insurance model inherits both sets of tradeoffs — it doesn't close either one.
Hana Field: No, and I'm not saying it closes them — but I want to push back on treating 'manages better' as if it's nothing, because that's actually what policy is for. You can't architect away a structural constraint, so the question becomes: can you reduce what a real person feels when it lands on them? And the social insurance model — Germany, Netherlands, Switzerland — those systems emerged specifically from the mid-century moment when governments decided healthcare was a public good, not a commodity. They were trying to hold both things.
Iris Holm: They were. And they're stuck with the architecture they built. Path dependency — switching now is politically catastrophic. Even a poorly performing system is almost impossible to restructure once the institutions are embedded.
Hana Field: Right — but that cuts both ways, doesn't it? Because the U.S. is also stuck. The coverage gaps aren't going anywhere either.
Iris Holm: Fair. No system escapes its own history. OECD data is unambiguous — publicly administered systems and compulsory private insurance systems each outperform the other on different metrics. Different metrics. Not the same ones.
Hana Field: So the hybrid is better at — what, exactly? Smoothing the experience of the tradeoff for the median person while still leaving real gaps at the edges?
Iris Holm: That's a precise way to put it, actually. The edges are still rationed. The innovation incentive is still partially dampened by the compulsory structure. The tradeoff is managed — not closed. That distinction matters.
Hana Field: It does — and I'll take that framing. Managing versus resolving. But the person who, in Germany or the Netherlands, doesn't face financial ruin from a diagnosis — that's not nothing. The WHO's framing for universal health coverage — essential services without financial hardship — Germany is closer to that than most. The gap stays open, I accept that, but 'closer' still matters.
Iris Holm: Closer matters. I won't dispute that. But 'closer' is not an answer — it's a position on a spectrum that has no end. The structural fork that emerged in the mid-twentieth century, the one every Western European system had to choose at, is still producing consequences right now. No hybrid has bridged it. They've built more comfortable ground to stand on while the gap runs underneath.
Hana Field: And that's actually where I want to land, I think — not on which system wins, because we've established that's the wrong question, but on whether citizens even know what was chosen on their behalf. Like, the equity-efficiency tradeoff is structural, fine, I accept that. But does the person in the NHS clinic know her country chose equity of distribution over innovation dynamism? Does the uninsured American know his country chose the opposite? Because I don't think they do, and I'm not sure that's an accident.
Iris Holm: It's not an accident. Systems are designed to obscure the rationing. Not advertise it.
Hana Field: Wait — designed to obscure it? That's a strong claim.
Iris Holm: Look — the NHS doesn't publish a list that says 'we chose waiting lists over drug access.' Canada's Medicare doesn't mail every citizen a document explaining that provincial rationing mechanisms are the price of the single-payer pool. The WHO frames universal health coverage as a right, which is a value claim, not a disclosure. The relevant policy question — the one nobody is actually asking — is not which system performs better on some OECD composite. It's how transparent a country is about what it is sacrificing. Whether citizens understand the choice that was made on their behalf.
Hana Field: And most don't. I mean — most don't, right? That's just true.
Iris Holm: Most don't. And I think if you made it explicit — actually told people, 'your country chose equity of distribution, and the cost is that a drug available in Boston won't be available here' — you'd get a different political conversation. Maybe. Or at least an honest one.
Hana Field: Yeah. And that's — I mean, that's where I keep arriving and not quite settling, because every nation is making that choice, equity versus innovation dynamism, and no system has resolved both simultaneously, and the thing that unsettles me is that the people living inside those systems mostly inherited the choice. They didn't make it. And I don't know what to do with that.
Iris Holm: Every country has decided which form of inequality it can live with. Most citizens just haven't been asked.
